ECSP19078502A - Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso - Google Patents

Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso

Info

Publication number
ECSP19078502A
ECSP19078502A ECSENADI201978502A ECDI201978502A ECSP19078502A EC SP19078502 A ECSP19078502 A EC SP19078502A EC SENADI201978502 A ECSENADI201978502 A EC SENADI201978502A EC DI201978502 A ECDI201978502 A EC DI201978502A EC SP19078502 A ECSP19078502 A EC SP19078502A
Authority
EC
Ecuador
Prior art keywords
methods
antibodies against
stable formulations
programmed death
death receptor
Prior art date
Application number
ECSENADI201978502A
Other languages
English (en)
Spanish (es)
Inventor
K Sharma Manoj
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64016286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP19078502(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ECSP19078502A publication Critical patent/ECSP19078502A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ECSENADI201978502A 2017-05-02 2019-10-31 Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso ECSP19078502A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762500238P 2017-05-02 2017-05-02

Publications (1)

Publication Number Publication Date
ECSP19078502A true ECSP19078502A (es) 2019-12-27

Family

ID=64016286

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201978502A ECSP19078502A (es) 2017-05-02 2019-10-31 Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso

Country Status (26)

Country Link
US (3) US11633476B2 (enExample)
EP (1) EP3618808A4 (enExample)
JP (2) JP7483376B2 (enExample)
KR (2) KR20250126869A (enExample)
CN (1) CN110869002A (enExample)
AU (2) AU2018263862B2 (enExample)
BR (1) BR112019022972A2 (enExample)
CA (1) CA3062160A1 (enExample)
CL (1) CL2019003142A1 (enExample)
CO (1) CO2019012151A2 (enExample)
CR (1) CR20190497A (enExample)
DO (1) DOP2019000280A (enExample)
EA (1) EA201992590A1 (enExample)
EC (1) ECSP19078502A (enExample)
GE (1) GEP20247693B (enExample)
IL (2) IL317348A (enExample)
JO (1) JOP20190260A1 (enExample)
MA (1) MA50663A (enExample)
MX (3) MX2019013028A (enExample)
MY (1) MY202279A (enExample)
NI (1) NI201900112A (enExample)
PE (3) PE20240813A1 (enExample)
PH (1) PH12019502484A1 (enExample)
SG (1) SG11201910182RA (enExample)
UA (1) UA128202C2 (enExample)
WO (1) WO2018204368A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354509B2 (en) 2007-06-18 2013-01-15 Msd Oss B.V. Antibodies to human programmed death receptor PD-1
EP4613778A3 (en) 2012-10-25 2025-12-17 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
RS63212B1 (sr) 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
AU2016305697B2 (en) 2015-08-11 2023-02-02 WuXi Biologics Ireland Limited Novel anti-PD-1 antibodies
JP6897570B2 (ja) 2015-12-18 2021-06-30 アステラス製薬株式会社 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物
TWI773695B (zh) 2016-10-12 2022-08-11 美商生物維瑞提夫美國公司 抗Ｃ１ｓ抗體及其使用方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SG11201909955XA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
AU2019274826A1 (en) * 2018-05-25 2021-01-07 Dr. Reddy's Laboratories Ltd. Stable fusion protein formulation
RU2766680C1 (ru) 2018-07-25 2022-03-15 Алтеоген, Инк Новые варианты гиалуронидазы и содержащая их фармацевтическая композиция
WO2020097139A1 (en) 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
US20210380694A1 (en) * 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JOP20210229A1 (ar) 2019-02-18 2023-01-30 Lilly Co Eli صيغة جسم مضاد علاجي
EP4461811A3 (en) * 2019-03-25 2025-01-08 Alteogen, Inc Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
KR20210145187A (ko) * 2019-03-29 2021-12-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도
GB201906835D0 (en) * 2019-05-15 2019-06-26 Ucb Biopharma Sprl Dry microparticles
WO2021067775A1 (en) * 2019-10-02 2021-04-08 Alamab Therapeutics, Inc. Anto-connexin antibody formulations
EP4074338A4 (en) * 2019-12-13 2024-03-06 Samsung Bioepis Co., Ltd. PHARMACEUTICAL PREPARATION OF STABLE ANTI-PD-1 ANTIBODY
EP4077388A1 (en) * 2019-12-18 2022-10-26 Tesaro, Inc. Biopharmaceutical compositions and related methods
EP4076385B1 (en) 2019-12-20 2025-12-10 Formycon AG Formulations of anti-pd1 antibodies
IL293367A (en) * 2019-12-20 2022-07-01 Anthos Therapeutics Inc Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
EP4096646A1 (en) * 2020-01-27 2022-12-07 Genentech, Inc. Methods for treatment of cancer with an anti-tigit antagonist antibody
KR20210097882A (ko) * 2020-01-30 2021-08-10 삼성바이오에피스 주식회사 안정한 항-pd-1 항체 약제학적 제제
EP4115903A4 (en) * 2020-03-04 2023-12-20 Shanghai Henlius Biotech, Inc. Pharmaceutical formulation comprising bevacizumab
PE20231076A1 (es) 2020-05-26 2023-07-17 Boehringer Ingelheim Int Anticuerpos anti-pd-1
US20230272106A1 (en) * 2020-06-19 2023-08-31 Sinocelltech Ltd Stable formulation for recombinant anti-pd-1 monoclonal antibody
EP4188544A4 (en) * 2020-07-31 2024-09-11 Alamab Therapeutics, Inc. ANTI-CONNEXIN ANTIBODY FORMULATIONS
TW202214298A (zh) * 2020-07-31 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 抗ｐｄ－１抗體醫藥組成物及其用途
KR102649603B1 (ko) 2020-08-07 2024-03-21 (주)알테오젠 재조합 히알루로니다제의 생산 방법
CN112285224A (zh) * 2020-10-02 2021-01-29 朱吉安 一种抗pd-1单克隆抗体药物的质量标准检测方法
CN116635077A (zh) * 2020-11-10 2023-08-22 赛诺菲 Ceacam5抗体-药物缀合物制剂
EP4008345A1 (en) * 2020-12-03 2022-06-08 Hexal AG Novel formulations for antibodies
CA3201348A1 (en) * 2020-12-28 2022-07-07 Masano HUANG Antibody compositions and methods of use thereof
EP4284834A1 (en) 2021-01-29 2023-12-06 Merck Sharp & Dohme LLC Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
TW202305009A (zh) 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
TW202308692A (zh) * 2021-04-27 2023-03-01 俄羅斯聯邦商拜奧卡德聯合股份公司 包含帕博利珠單抗（ｐｅｍｂｒｏｌｉｚｕｍａｂ）的藥學組成物及其用途
WO2022271544A1 (en) * 2021-06-21 2022-12-29 Bristol-Myers Squibb Company Use of sucrose, mannitol and glycine to reduce reconstitution time of high concentration lyophilized biologics drug products
KR20240024941A (ko) 2021-06-23 2024-02-26 포르미콘 아게 항-pd1 항체의 제제
US12364756B2 (en) * 2021-07-09 2025-07-22 Macrogenics, Inc. Pharmaceutical compositions of a PD-1 antibody and use of the same
CA3249885A1 (en) 2022-03-07 2023-09-14 Mabxience Res S L STABLE ANTIBODY FORMULATIONS
IL316318A (en) * 2022-04-14 2024-12-01 Beigene Switzerland Gmbh Stable concentrated formulations of sodium chloride and PD-1 antibodies and their uses
AU2023252259A1 (en) * 2022-04-14 2024-11-07 Beigene Switzerland Gmbh Stable high concentration arginine formulations containing pd-1 antibody and methods of use thereof
JP2025520434A (ja) * 2022-06-15 2025-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体製剤
CA3260807A1 (en) * 2022-07-01 2024-01-04 Amgen Inc ANTI-PD-1 ANTIBODY FORMULATIONS
TW202409078A (zh) * 2022-07-18 2024-03-01 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗gremlin1抗體的藥物製劑
WO2024102675A1 (en) * 2022-11-07 2024-05-16 Upstream Bio, Inc. Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
AU2023413756A1 (en) 2022-12-21 2025-07-10 Formycon Ag Formulations of anti-pd1 antibodies
IL322410A (en) 2023-02-16 2025-09-01 Sun Pharmaceutical Ind Ltd Stable protein complexes containing an antibody against PD1
WO2025106775A1 (en) * 2023-11-17 2025-05-22 Orionis Biosciences, Inc. Pd-l1-based chimeric protein formulations
WO2025140495A1 (zh) * 2023-12-28 2025-07-03 齐鲁制药有限公司 稳定的抗pd-1抗体的药物组合物
WO2025143921A1 (ko) * 2023-12-29 2025-07-03 (주)셀트리온 안정한 약제학적 제제
WO2025174319A1 (en) * 2024-02-16 2025-08-21 Xbrane Biopharma Ab Stable antibody formulation for intravenous use comprising nivolumab, histidine, sucrose, polysorbate and methionine
SE2430078A1 (en) * 2024-02-16 2025-08-17 Xbrane Biopharma Ab Stable antibody formulation comprising nivolumab, histidine, sucrose, polysorbate and methionine
WO2025191489A1 (en) * 2024-03-15 2025-09-18 Lupin Limited Pharmaceutical formulation of anti-pd-1 antibody

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401820A (en) * 1981-01-23 1983-08-30 Tanabe Seiyaku Co., Ltd. Process for racemizing optically active α-amino acids or a salt thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
DE68920693T2 (de) 1988-03-30 1995-05-24 Toray Industries Gefriergetrocknete Zusammensetzung, die ein mit Meerrettichperoxydase markiertes Fab'-Fragment eines gegen menschliches Beta-Interferon gerichteten Antikörpers und Trehalose enthält; EIA Kit, der diese Zusammensetzung enthält.
JPH03504605A (ja) 1988-05-27 1991-10-09 セントカー・インコーポレーテツド 抗体産生物の凍結乾燥した配合物
ES2191016T3 (es) 1992-09-16 2003-09-01 Scripps Research Inst Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial.
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
SI2275119T1 (sl) 1995-07-27 2013-12-31 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
ATE194291T1 (de) 1995-09-18 2000-07-15 Intracel Corp Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
JP5149470B2 (ja) 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
ATE420894T1 (de) 1999-03-11 2009-01-15 Schering Corp Cytokine aus säugetieren, verwandte reagenzien und verfahren
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
CN100529076C (zh) 1999-09-09 2009-08-19 先灵公司 哺乳动物细胞因子、相关试剂和方法
WO2001030393A2 (en) 1999-10-22 2001-05-03 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6875432B2 (en) 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
CA2433353C (en) 2000-12-28 2017-03-21 Altus Biologics, Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
EP1801123A3 (en) 2000-12-28 2007-11-21 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
AU2002327171A1 (en) 2001-05-01 2003-01-02 Medimmune, Inc. Crystals and structure of synagis fab
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
NZ530700A (en) 2001-06-21 2009-02-28 Altus Pharmaceuticals Inc Spherical protein particles and methods of making and using them
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
DE10207178A1 (de) 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
DE60322513D1 (de) 2002-02-27 2008-09-11 Immunex Corp Stabilisierte TNFR-Fc Formulierung mit Arginin
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004019861A2 (en) 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
EP1539228B1 (en) 2002-09-11 2010-12-29 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
PT2236154T (pt) 2003-02-10 2018-06-26 Biogen Ma Inc Formulação de imunoglobulinas e método de preparação das mesmas
NZ541898A (en) 2003-03-10 2008-07-31 Schering Corp Uses of IL-23 antagonists for the manufacture of a medicament for the treatment of tumors
ES2349779T5 (es) 2003-04-04 2013-11-26 Genentech, Inc. Formulaciones de anticuerpos y de proteínas a concentración elevada
NZ543498A (en) 2003-05-14 2007-06-29 Immunogen Inc A conjugate comprising an antibody chemically coupled to a maytansinoid
EP1498123A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
ATE518888T1 (de) 2003-10-09 2011-08-15 Chugai Pharmaceutical Co Ltd Stabilisierte lösung mit hoher igm-konzentration
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2005047324A2 (en) 2003-11-10 2005-05-26 Schering Corp Interleukin-10 antibodies
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
EP1712240B1 (en) 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
HUE026132T2 (en) 2004-01-07 2016-05-30 Novartis Vaccines & Diagnostics Inc M-CSF-specific monoclonal antibody and its uses
WO2005077414A1 (de) 2004-02-12 2005-08-25 Merck Patent Gmbh Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern
AU2005215527B2 (en) 2004-02-17 2011-04-07 Merck Sharp & Dohme Corp. Methods of modulating IL-23 activity; related reagents
JP4857259B2 (ja) 2004-03-24 2012-01-18 アボット バイオセラピューティクス コーポレイション 癌細胞増殖を阻害するための抗α５β１抗体の使用
US7691379B2 (en) 2004-04-12 2010-04-06 Medimmune, Llc Anti-IL-9 antibody formulations
US20110142858A1 (en) 2004-06-07 2011-06-16 Ramot At Tel Aviv University Ltd. Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
AP2007003890A0 (en) 2004-07-30 2007-02-28 Rinat Neuroscience Corp Antibodies directed against amy-loid-beta peptide and methods using same
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080057070A1 (en) 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
JP2008528638A (ja) 2005-01-28 2008-07-31 ワイス ポリペプチドの安定化液体処方
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
LT2620450T (lt) 2005-03-08 2019-02-11 Pfizer Products Inc. Anti-ctla-4 antikūnų kompozicijos
AU2005330672B2 (en) 2005-04-18 2011-07-28 Yeda Research And Development Company Limited Stabilized anti-hepatitis B (HBV) antibody formulations
BRPI0608376A8 (pt) 2005-04-22 2018-10-16 Lilly Co Eli composição de ligação, método de uso de uma composição de ligação, e, kit de detecção
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
AU2006255415B2 (en) 2005-06-07 2011-10-06 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
JP2008546699A (ja) 2005-06-15 2008-12-25 シェーリング コーポレイション 抗ｉｇｆ１ｒ抗体処方物
HUE042561T2 (hu) 2005-06-30 2019-07-29 Janssen Biotech Inc Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
US20070190047A1 (en) 2005-07-29 2007-08-16 Amgen, Inc. Formulations that inhibit protein aggregation
EP1917030A4 (en) 2005-08-03 2011-03-09 Immunogen Inc IMMUNKONJUGATFORMULIERUNGEN
DK1937721T3 (da) 2005-08-25 2010-10-18 Lilly Co Eli Anti-IL-23 antistoffer
ES2619845T3 (es) 2005-08-31 2017-06-27 Merck Sharp & Dohme Corp. Anticuerpos anti-IL-23 diseñados por ingeniería genética
EP1933868A2 (en) 2005-09-12 2008-06-25 NovImmune SA Anti-cd3 antibody formulations
US20080248048A1 (en) 2005-09-30 2008-10-09 Astrazeneca Ab Interleukin-13 Antibody Composition
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
ES2807928T3 (es) 2005-12-29 2021-02-24 Janssen Biotech Inc Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
KR20080098504A (ko) 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
EP1998806A1 (en) 2006-03-28 2008-12-10 F. Hoffmann-Roche AG Anti-igf-1r human monoclonal antibody formulation
MEP39508A (en) 2006-04-21 2011-02-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
JP2009534390A (ja) 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
EP2081553B1 (en) 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
CL2007002881A1 (es) 2006-10-20 2008-05-09 Amgen Inc Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodo
EP2089428B1 (en) 2006-10-27 2013-11-20 AbbVie Biotechnology Ltd Crystalline anti-htnfalpha antibodies
CA2668947C (en) 2006-12-05 2017-02-07 Crucell Holland B.V. Liquid anti-rabies antibody formulations
KR20090088950A (ko) 2006-12-14 2009-08-20 쉐링 코포레이션 가공된 항-ｔｓｌｐ 항체
CA2790018C (en) 2006-12-21 2015-02-03 Amgen Inc. Formulations
CL2008000058A1 (es) 2007-01-09 2008-05-23 Wyeth Corp Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden.
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
WO2008100562A2 (en) 2007-02-14 2008-08-21 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
EP2064242A1 (en) 2007-02-23 2009-06-03 Schering Corporation Engineered anti-il-23p19 antibodies
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
NZ598881A (en) 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
EP2077859A4 (en) 2007-03-30 2010-11-24 Medimmune Llc ANTIBODY FORMULATION
PT2170390T (pt) 2007-06-14 2019-02-12 Biogen Ma Inc Formulações com anticorpo natalizumab
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US8354509B2 (en) 2007-06-18 2013-01-15 Msd Oss B.V. Antibodies to human programmed death receptor PD-1
AU2008269086B2 (en) 2007-06-25 2014-06-12 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
US20100286038A1 (en) 2007-09-21 2010-11-11 Valentyn Antochshuk Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
WO2009114040A2 (en) 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
EP2234600B1 (en) 2007-12-21 2014-08-20 F. Hoffmann-La Roche AG Antibody formulation
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
AU2008342942A1 (en) 2007-12-28 2009-07-09 Biolnvent International Ab Formulation
CN102202643A (zh) 2008-02-07 2011-09-28 安姆根有限公司 稳定化的蛋白组合物
CA2715166C (en) 2008-02-11 2017-05-16 Curetech Ltd. Monoclonal antibodies for tumor treatment
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
SG10202112838YA (en) 2008-04-09 2021-12-30 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
RU2010153580A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двумя вариабельными доменами и их применение
US8460886B2 (en) 2008-07-04 2013-06-11 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers
EP2331078B1 (en) 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
RU2518278C2 (ru) 2008-09-19 2014-06-10 Пфайзер Инк. Стабильный жидкий препарат антитела
BR122018013284B1 (pt) 2008-10-29 2022-03-03 Ablynx N.V Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab
WO2010062372A2 (en) 2008-11-03 2010-06-03 President And Fellows Of Harvard College Methods for modulating nf-kb using gibberellins
MX2011005056A (es) 2008-11-17 2011-05-31 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas.
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
MX2011009312A (es) * 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
KR20110128333A (ko) 2009-03-06 2011-11-29 제넨테크, 인크. 항체 제제
EP2230312A1 (en) 2009-03-19 2010-09-22 Helmholtz-Zentrum für Infektionsforschung GmbH Probe compound for detecting and isolating enzymes and means and methods using the same
SG175188A1 (en) 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US9155745B2 (en) 2009-06-16 2015-10-13 Universite De Geneve Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
US20120183531A1 (en) 2009-07-14 2012-07-19 Biogen Idee Ma Inc Methods for Inhibiting Yellow Color Formation in a Composition
EP2458990B1 (en) 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011024862A1 (ja) 2009-08-31 2011-03-03 三洋化成工業株式会社 タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及び液体洗剤組成物、並びに、この安定化剤を用いるタンパク質の安定化方法
RU2646139C1 (ru) 2009-09-03 2018-03-01 Мерк Шарп И Доум Корп. Анти-gitr-антитела
WO2011028962A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody coformulations
KR101530417B1 (ko) 2009-09-15 2015-06-19 알테아 테크놀로지스, 인코포레이티드 단백질 ａ 결정 및 가교 결합된 결정 및 이들의 사용 방법
NZ599761A (en) 2009-11-04 2014-04-30 Merck Sharp & Dohme Engineered anti-tslp antibody
AR079556A1 (es) 2009-12-21 2012-02-01 Genentech Inc Formacion de anticuerpos
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
US8399712B2 (en) 2010-02-03 2013-03-19 Laurus Labs Private Limited Pterostilbene cocrystals
UY33280A (es) 2010-03-17 2011-10-31 Abbott Res Bv Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
JP2013541493A (ja) 2010-06-17 2013-11-14 フュジアンス バイオメディカルズ インコーポレイテッド 抗ウイルス剤として有用な化合物、組成物、及び使用の方法
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
FR2962908A1 (fr) 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
WO2012018538A2 (en) 2010-07-26 2012-02-09 Schering Corporation Bioassays for determining pd-1 modulation
WO2012047954A1 (en) 2010-10-06 2012-04-12 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
US9145457B2 (en) 2011-03-25 2015-09-29 Amgen Inc. Sclerostin antibody crystals and formulations thereof
PL2691112T3 (pl) 2011-03-31 2018-09-28 Merck Sharp & Dohme Corp. Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane
EP2694708A4 (en) 2011-04-07 2014-10-01 Glaxosmithkline Llc FORMULATIONS WITH REDUCED VISCOSITY
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
AU2012328570B2 (en) 2011-10-27 2017-08-31 Massachusetts Institute Of Technology Amino acid derivatives functionalized on the n-terminus capable of forming drug encapsulating microspheres and uses thereof
MX357393B (es) 2012-01-23 2018-07-06 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti - ang2.
AU2013255413C1 (en) 2012-03-07 2016-03-24 Cadila Healthcare Limited Pharmaceutical formulations of TNF-alpha antibodies
WO2013151999A1 (en) 2012-04-02 2013-10-10 President And Fellows Of Harvard College Cancer treatment and immune system regulation through fat10 pathway inhibition
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
JP6148729B2 (ja) 2012-07-04 2017-06-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 共有結合している抗原−抗体結合体
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
WO2014031718A1 (en) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9649383B2 (en) 2012-11-19 2017-05-16 Merck Sharp & Dohme Corp. Liquid formulations for TNFR:Fc fusion proteins
WO2014093206A1 (en) 2012-12-13 2014-06-19 Merck Sharp & Dohme Corp. Lyophilized spherical pellets of anti-il-23 antibodies
US9700633B2 (en) 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
MX385713B (es) 2013-03-13 2025-03-18 Seagen Inc Ciclodextrina y formulaciones de conjugados anticuerpo-fármaco.
US10010608B2 (en) * 2013-05-31 2018-07-03 Merck Sharp & Dohme Corp. Combination therapies for cancer
WO2015009856A2 (en) 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
ES2728578T3 (es) 2013-09-20 2019-10-25 Bristol Myers Squibb Co Combinación de anticuerpos anti-LAG-3 y anticuerpos anti-PD-1 para tratar tumores
US9782470B2 (en) 2013-10-16 2017-10-10 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
WO2015143343A2 (en) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
RU2589691C2 (ru) 2014-06-16 2016-07-10 Общество с ограниченной ответственностью "Промоген-МАТ" Стабильная композиция антитела, специфически связывающегося с her2 рецепторами, и способ ее получения
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
MA40344A (fr) * 2014-07-18 2016-01-21 Advaxis Inc Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
DK3179992T3 (da) 2014-08-11 2022-07-11 Acerta Pharma Bv Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor
CA2957722C (en) 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anti-tigit antibodies
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
KR102644115B1 (ko) 2014-12-23 2024-03-05 브리스톨-마이어스 스큅 컴퍼니 Tigit에 대한 항체
EP3237000A1 (en) 2014-12-23 2017-11-01 Pfizer Inc Stable aqueous antibody formulation for anti tnf alpha antibodies
JP2018502123A (ja) 2015-01-20 2018-01-25 イミューンエクサイト， インコーポレイテッド 癌免疫療法のための組成物及び方法
PL3258951T3 (pl) 2015-02-19 2020-07-27 Compugen Ltd. Przeciwciała anty-pvrig i sposoby ich zastosowania
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2016161410A2 (en) * 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
RS60753B1 (sr) * 2015-04-17 2020-10-30 Bristol Myers Squibb Co Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
KR20250107941A (ko) 2015-04-28 2025-07-14 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용한 pd-l1-양성 흑색종의 치료
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
WO2017009813A1 (en) 2015-07-16 2017-01-19 Laurus Labs Private Limited Novel caffeine cocrystals and their polymorphic forms
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
WO2017030823A2 (en) 2015-08-14 2017-02-23 Merck Sharp & Dohme Corp. Anti-tigit antibodies
KR20180080189A (ko) 2015-09-01 2018-07-11 퍼스트 웨이브 바이오, 인코포레이티드 이상 염증 반응과 연관된 질환을 치료하기 위한 방법 및 조성물
AU2016316730B2 (en) 2015-09-02 2023-05-25 Immutep S.A.S. Anti-LAG-3 Antibodies
WO2017048824A1 (en) 2015-09-14 2017-03-23 Compass Therapeutics Llc COMPOSITIONS AND METHODS FOR TREATING CANCER VIA ANTAGONISM OF THE CD155/TIGIT PATHWAY AND TGF-β
PH12022553648A1 (en) 2015-09-25 2024-03-11 Genentech Inc Anti-tigit antibodies and methods of use
RU2731418C2 (ru) 2015-09-28 2020-09-02 Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
US20170097333A1 (en) 2015-09-28 2017-04-06 Merck Sharp & Dohme Corp. Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
HUE058755T2 (hu) 2015-10-01 2022-09-28 Potenza Therapeutics Inc Anti-tigit antigénkötõ proteinek és felhasználásuk módszerei
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
AU2016359235B2 (en) 2015-11-25 2022-09-15 Ligachem Biosciences Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
US20190010224A1 (en) 2015-12-22 2019-01-10 Merck Sharp & Dohme Corp. Formulations of engineered anti-il-10 antibodies
TWI657096B (zh) 2016-01-21 2019-04-21 輝瑞股份有限公司 對表皮生長因子受體變異體iii具特異性之抗體類及彼等之用途
KR20220103806A (ko) 2016-05-18 2022-07-22 베링거 인겔하임 인터내셔날 게엠베하 암 치료용 항-pd1 및 항-lag3 항체
DK3468586T3 (da) 2016-06-14 2024-10-21 Xencor Inc Bispecifikke checkpoint-hæmmer-antistoffer
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
UA128669C2 (uk) 2016-10-14 2024-09-25 Ксенкор, Інк. ГЕТЕРОДИМЕРНИЙ Fc-ЗЛИТИЙ БІЛОК IL15/IL15Ra
WO2018091729A2 (en) 2016-11-21 2018-05-24 Zaklady Farmaceutyczne Polpharma Sa Aqueous pharmaceutical formulations
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
CN112057419B (zh) 2017-03-01 2023-08-22 免疫医疗有限公司 单克隆抗体的配制品
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
SG11201909955XA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3618866A4 (en) 2017-05-02 2021-07-14 Merck Sharp & Dohme Corp. STABLE FORMULATIONS OF ANTI-CTLA4 ANTIBODIES ALONE AND IN COMBINATION WITH PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHOD OF USING THEREOF
BR112020004325A2 (pt) 2017-09-05 2020-10-06 Merck Sharp & Dohme Corp. compostos para reduzir a viscosidade de formulações biológicas
WO2020097139A1 (en) 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies

Also Published As

Publication number Publication date
CL2019003142A1 (es) 2020-07-10
BR112019022972A2 (pt) 2020-05-26
SG11201910182RA (en) 2019-11-28
DOP2019000280A (es) 2019-12-15
IL317348A (en) 2025-01-01
CR20190497A (es) 2020-01-20
MY202279A (en) 2024-04-22
MX2024007358A (es) 2024-06-28
MX2019013028A (es) 2020-02-05
US20230321234A1 (en) 2023-10-12
EP3618808A1 (en) 2020-03-11
PE20200513A1 (es) 2020-03-05
CO2019012151A2 (es) 2020-02-07
EA201992590A1 (ru) 2020-04-08
JP2024102215A (ja) 2024-07-30
JOP20190260A1 (ar) 2019-10-31
PH12019502484A1 (en) 2020-07-20
EP3618808A4 (en) 2021-05-26
MX2024007356A (es) 2024-06-28
MA50663A (fr) 2021-05-26
IL270253B1 (en) 2025-01-01
PE20240814A1 (es) 2024-04-18
JP2020518599A (ja) 2020-06-25
KR20250126869A (ko) 2025-08-25
US20200147213A1 (en) 2020-05-14
KR102847571B1 (ko) 2025-08-21
KR20190142392A (ko) 2019-12-26
UA128202C2 (uk) 2024-05-08
PE20240813A1 (es) 2024-04-18
AU2025205140A1 (en) 2025-07-24
CA3062160A1 (en) 2018-11-08
US20230263887A1 (en) 2023-08-24
US11633476B2 (en) 2023-04-25
AU2018263862B2 (en) 2025-04-10
NI201900112A (es) 2020-02-04
CN110869002A (zh) 2020-03-06
JP7483376B2 (ja) 2024-05-15
IL270253B2 (en) 2025-05-01
WO2018204368A1 (en) 2018-11-08
AU2018263862A1 (en) 2019-11-21
GEP20247693B (en) 2024-11-11
IL270253A (enExample) 2019-12-31

Similar Documents

Publication Publication Date Title
DOP2019000280A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
CL2021003196A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850)
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
CR20190376A (es) Formulaciones de anticuerpos de her2 subcutáneas
CL2021003042A1 (es) Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
CO2023003576A2 (es) Formulaciones estables de anticuerpos programados del receptor de muerte 1 (pd-1) y variantes de hialuronidasa y fragmentos de las mismas y métodos de uso de las mismas
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
CO2020006865A2 (es) Composiciones y métodos para el agotamiento de células cd5+
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CL2024000459A1 (es) Tubulisinas y conjugados de proteína-tubulisina.
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
MX2025003354A (es) Anticuerpos que se unen a 5t4
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
BR112017004590A2 (pt) métodos para o tratamento de doença autoimune com o uso de um anticorpo de domínio direcionado contra cd40l
MX2025010218A (es) Anticuerpos multiespecificos anti-cldn6 y anti-cd3 y metodos de uso
EA201992068A1 (ru) Взаимодействующие с гликанами соединения и способы их применения
AR104931A1 (es) Métodos para tratar cáncer usando anticuerpos anti-ox40 y antagonistas de unión al eje pd-1